Showing results (91-100 of 424) with videos related to
Sort By:
Pageof 43
Molecular Cancer Therapeutics|June 1, 2023
Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and BiomarkersBlessie Elizabeth Nelson, Jacob J Adashek, Aakash Akshay Sheth, et al.JCO Precision Oncology|July 14, 2022
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced CancersMohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, et al.Sultan Qaboos University Medical Journal|September 1, 2023
Long-Term Survival in Patients with Cancers: Surveillance, epidemiology and end results-based analysisRokia A Sakr, Abdelrahman A Nasr, Eman I Zineldin, et al.Journal of Clinical Medicine|June 19, 2024
Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase InhibitorsKalevi Kairemo, Mohamed Gouda, Hubert H Chuang, et al.Trends in Cancer|December 10, 2021
Impact of tissue-agnostic approvals for patients with sarcomaRoberto Carmagnani Pestana, Juliana Rodrigues Beal, Amanda Parkes, et al.Cell|January 18, 2020
The Master Observational Trial: A New Class of Master Protocol to Advance Precision MedicineDane Dickson, Jennifer Johnson, Raymond Bergan, et al.British Journal of Cancer|March 14, 2023
The emerging role of PI3K inhibitors for solid tumour treatment and beyondCarmen Belli, Matteo Repetto, Santosh Anand, et al.Cell|April 4, 2020
Snapshot: Trial Types in Precision MedicineDane Dickson, Jennifer Johnson, Raymond Bergan, et al.JAMA Network Open|November 12, 2021
Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung CancerSreeram Ramagopalan, Alind Gupta, Paul Arora, et al.Cancers|November 27, 2024
Association of Antibody-Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?Aakash Desai, Vivek Subbiah, Sinchita Roy-Chowdhuri, et al.Pageof 43